

A guide to ICD-10-CM coding for patients who are prescribed PRALUENT for an indication approved by the US Food and Drug Administration

PRALUENT ICD-10-CM pocket guide

The coding information discussed in this document is provided for informational purposes only, is subject to change, and should not be construed as legal advice. The codes listed herein may not apply to all patients or to all health plans; providers should exercise independent clinical judgment when selecting codes and submitting claims to accurately reflect the services and products furnished to a specific patient.

Indications and Usage

PRALUENT is indicated:

- to reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease.
- as an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C) lowering therapies in adults with primary hyperlipidemia including heterozygous familial hypercholesterolemia (HeFH) to reduce LDL-C.
- as an adjunct to other LDL-C-lowering therapies in adults with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C.

Important Safety Information

PRALUENT is contraindicated in patients with a history of a serious hypersensitivity reaction to alirocumab or any of the excipients in PRALUENT. Hypersensitivity reactions, including hypersensitivity vasculitis, angioedema, and other hypersensitivity reactions requiring hospitalization, have been reported with PRALUENT treatment. If signs or symptoms of serious allergic reactions occur, discontinue treatment with PRALUENT, treat according to the standard of care, and monitor until signs and symptoms resolve.

ICD-10-CM=International Classification of Diseases, Tenth Revision, Clinical Modification.

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information.


Praluent[®]
(alirocumab) Injection 75mg/mL
150mg/mL

Primary and secondary ICD-10-CM codes

Section 1	Disorders of lipoprotein metabolism and other lipidemias	3
	Transient cerebral ischemic attacks and related syndromes	3
	Ischemic heart diseases	3
	Angina pectoris	3
	Acute myocardial infarction	3
	Subsequent ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction	3
	Certain current complications following ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction (within the 28-day period)	3
	Other acute ischemic heart diseases	4
	Chronic ischemic heart disease	4
Section 2	Cerebrovascular diseases	5
	Cerebral infarction	5
	Occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction	7
	Occlusion and stenosis of cerebral arteries, not resulting in cerebral infarction	8
	Other cerebrovascular diseases	8
Section 3	Diseases of arteries, arterioles, and capillaries	9
	Atherosclerosis	9
	Other peripheral vascular diseases	15
Section 4	Family history of other specific disorders	16
	Presence of cardiac and vascular implants and grafts	16
	Other postprocedural states	16

Please use as many secondary codes as needed to appropriately describe your patient's condition.

Need additional support?



Visit
PRALUENThcp.com

OR



Call
1-844-PRALUENT (1-844-772-5836),
Monday-Friday, 8 AM-8 PM Eastern time

Brought to you by Regeneron Pharmaceuticals, Inc.

Please see Important Safety Information throughout and [click here](#) for full Prescribing Information.



E78: Disorders of lipoprotein metabolism and other lipidemias

E78.0	Pure hypercholesterolemia
E78.00	Pure hypercholesterolemia, unspecified
E78.01	Familial hypercholesterolemia
E78.2	Mixed hyperlipidemia
E78.4	Other hyperlipidemia
E78.5	Hyperlipidemia, unspecified

G45: Transient cerebral ischemic attacks and related syndromes

G45.0	Vertebro-basilar artery syndrome
G45.1	Carotid artery syndrome (hemispheric)
G45.2	Multiple and bilateral precerebral artery syndromes
G45.8	Other transient cerebral ischemic attacks and related syndromes
G45.9	Transient cerebral ischemic attack, unspecified

Ischemic heart diseases

I20: Angina pectoris

I20.0	Unstable angina
I20.1	Angina pectoris with documented spasm
I20.8	Other forms of angina pectoris
I20.9	Angina pectoris, unspecified

I21: Acute myocardial infarction

I21.0	ST elevation (STEMI) myocardial infarction of anterior wall
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall
I21.1	ST elevation (STEMI) myocardial infarction of inferior wall
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall
I21.2	ST elevation (STEMI) myocardial infarction of other sites
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery
I21.29	ST elevation (STEMI) myocardial infarction involving other sites
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site
I21.4	Non-ST elevation (NSTEMI) myocardial infarction
I21.9	Acute myocardial infarction, unspecified
I21.A	Other type of myocardial infarction
I21.A9	Other myocardial infarction type

I22: Subsequent ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction

I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall
I22.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified sites

I23: Certain current complications following ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction (within the 28-day period)

I23.7	Postinfarction angina
I23.8	Other current complications following acute myocardial infarction

Important Safety Information (cont'd)

The most commonly occurring adverse reactions in clinical trials in primary hyperlipidemia (including heterozygous familial hypercholesterolemia (HeFH)) ($\geq 5\%$ of patients treated with PRALUENT and occurring more frequently than with placebo) are nasopharyngitis, injection site reactions, and influenza.

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information.


Praluent[®]
(alirocumab) Injection 75mg/mL
150mg/mL

Ischemic heart diseases (cont'd)**I24: Other acute ischemic heart diseases****I24.8** Other forms of acute ischemic heart disease**I24.9** Acute ischemic heart disease, unspecified**I25: Chronic ischemic heart disease****I25.10** Atherosclerotic heart disease of native coronary artery without angina pectoris**I25.110** Atherosclerotic heart disease of native coronary artery with unstable angina pectoris**I25.111** Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm**I25.118** Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris**I25.119** Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris**I25.2** Old myocardial infarction**I25.700** Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris**I25.701** Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris with documented spasm**I25.708** Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of angina pectoris**I25.709** Atherosclerosis of coronary artery bypass graft(s), unspecified, with unspecified angina pectoris**I25.710** Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable angina pectoris**I25.711** Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris with documented spasm**I25.718** Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms of angina pectoris**I25.719** Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina pectoris**I25.720** Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable angina pectoris**I25.721** Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris with documented spasm**I25.728** Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms of angina pectoris**I25.729** Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris**I25.730** Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unstable angina pectoris**I25.731** Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris with documented spasm**I25.738** Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with other forms of angina pectoris**I25.739** Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris**I25.750** Atherosclerosis of native coronary artery of transplanted heart with unstable angina**I25.751** Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm**I25.758** Atherosclerosis of native coronary artery of transplanted heart with other forms of angina pectoris**I25.759** Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris**I25.760** Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina**I25.761** Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm**I25.768** Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris**I25.769** Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris**I25.790** Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris**I25.791** Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with documented spasm**I25.798** Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina pectoris**I25.799** Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris**I25.810** Atherosclerosis of coronary artery bypass graft(s) without angina pectoris**I25.811** Atherosclerosis of native coronary artery of transplanted heart without angina pectoris**I25.812** Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina pectoris**I25.83** Coronary atherosclerosis due to lipid rich plaque**I25.84** Coronary atherosclerosis due to calcified coronary artery lesion**Important Safety Information (cont'd)**

The most commonly occurring adverse reactions in the cardiovascular outcomes trial (>5% of patients treated with PRALUENT and occurring more frequently than placebo) were non-cardiac chest pain, nasopharyngitis, and myalgia.

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information.



Praluent[®]
(alirocumab) Injection 75mg/mL
150mg/mL

Cerebrovascular diseases

I63: Cerebral infarction

I63.0	Cerebral infarction due to thrombosis of precerebral arteries
I63.00	Cerebral infarction due to thrombosis of unspecified precerebral artery
I63.01	Cerebral infarction due to thrombosis of vertebral artery
I63.011	Cerebral infarction due to thrombosis of right vertebral artery
I63.012	Cerebral infarction due to thrombosis of left vertebral artery
I63.013	Cerebral infarction due to thrombosis of bilateral vertebral arteries
I63.019	Cerebral infarction due to thrombosis of unspecified vertebral artery
I63.02	Cerebral infarction due to thrombosis of basilar artery
I63.03	Cerebral infarction due to thrombosis of carotid artery
I63.031	Cerebral infarction due to thrombosis of right carotid artery
I63.032	Cerebral infarction due to thrombosis of left carotid artery
I63.033	Cerebral infarction due to thrombosis of bilateral carotid arteries
I63.039	Cerebral infarction due to thrombosis of unspecified carotid artery
I63.09	Cerebral infarction due to thrombosis of other precerebral artery
I63.10	Cerebral infarction due to embolism of unspecified precerebral artery
I63.111	Cerebral infarction due to embolism of right vertebral artery
I63.112	Cerebral infarction due to embolism of left vertebral artery
I63.113	Cerebral infarction due to embolism of bilateral vertebral arteries
I63.119	Cerebral infarction due to embolism of unspecified vertebral artery
I63.12	Cerebral infarction due to embolism of basilar artery
I63.131	Cerebral infarction due to embolism of right carotid artery
I63.132	Cerebral infarction due to embolism of left carotid artery
I63.133	Cerebral infarction due to embolism of bilateral carotid arteries
I63.139	Cerebral infarction due to embolism of unspecified carotid artery
I63.19	Cerebral infarction due to embolism of other precerebral artery
I63.2	Cerebral infarction due to unspecified occlusion or stenosis of precerebral arteries
I63.20	Cerebral infarction due to unspecified occlusion or stenosis of unspecified precerebral arteries
I63.21	Cerebral infarction due to unspecified occlusion or stenosis of vertebral arteries
I63.211	Cerebral infarction due to unspecified occlusion or stenosis of right vertebral artery
I63.212	Cerebral infarction due to unspecified occlusion or stenosis of left vertebral artery
I63.213	Cerebral infarction due to unspecified occlusion or stenosis of bilateral vertebral arteries
I63.219	Cerebral infarction due to unspecified occlusion or stenosis of unspecified vertebral arteries
I63.22	Cerebral infarction due to unspecified occlusion or stenosis of basilar artery
I63.23	Cerebral infarction due to unspecified occlusion or stenosis of carotid arteries
I63.231	Cerebral infarction due to unspecified occlusion or stenosis of right carotid arteries
I63.232	Cerebral infarction due to unspecified occlusion or stenosis of left carotid arteries
I63.233	Cerebral infarction due to unspecified occlusion or stenosis of bilateral carotid arteries
I63.239	Cerebral infarction due to unspecified occlusion or stenosis of unspecified carotid arteries
I63.29	Cerebral infarction due to unspecified occlusion or stenosis of other precerebral arteries

Important Safety Information (cont'd)

In the primary hyperlipidemia (including HeFH) clinical trials, local injection site reactions including erythema/redness, itching, swelling, and pain/tenderness were reported more frequently in patients treated with PRALUENT 75 mg and/or 150 mg every 2 weeks (7.2% versus 5.1% for PRALUENT and placebo, respectively). Few patients discontinued treatment because of these reactions (0.2% versus 0.4% for PRALUENT and placebo, respectively), but patients receiving PRALUENT had a greater number of injection site reactions, had more reports of associated symptoms, and had reactions of longer average duration than patients receiving placebo.

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information.

Praluent[®]
(alirocumab) Injection 75mg/mL
150mg/mL

I63: Cerebral infarction (cont'd)

I63.3	Cerebral infarction due to thrombosis of cerebral arteries
I63.30	Cerebral infarction due to thrombosis of unspecified cerebral artery
I63.31	Cerebral infarction due to thrombosis of middle cerebral artery
I63.311	Cerebral infarction due to thrombosis of right middle cerebral artery
I63.312	Cerebral infarction due to thrombosis of left middle cerebral artery
I63.313	Cerebral infarction due to thrombosis of bilateral middle cerebral arteries
I63.319	Cerebral infarction due to thrombosis of unspecified middle cerebral artery
I63.32	Cerebral infarction due to thrombosis of anterior cerebral artery
I63.321	Cerebral infarction due to thrombosis of right anterior cerebral artery
I63.322	Cerebral infarction due to thrombosis of left anterior cerebral artery
I63.323	Cerebral infarction due to thrombosis of bilateral anterior arteries
I63.329	Cerebral infarction due to thrombosis of unspecified anterior cerebral artery
I63.33	Cerebral infarction due to thrombosis of posterior cerebral artery
I63.331	Cerebral infarction due to thrombosis of right posterior cerebral artery
I63.332	Cerebral infarction due to thrombosis of left posterior cerebral artery
I63.333	Cerebral infarction due to thrombosis of bilateral posterior cerebral arteries
I63.339	Cerebral infarction due to thrombosis of unspecified posterior cerebral artery
I63.34	Cerebral infarction due to thrombosis of cerebellar artery
I63.341	Cerebral infarction due to thrombosis of right cerebellar artery
I63.342	Cerebral infarction due to thrombosis of left cerebellar artery
I63.343	Cerebral infarction due to thrombosis of bilateral cerebellar arteries
I63.349	Cerebral infarction due to thrombosis of unspecified cerebellar artery
I63.39	Cerebral infarction due to thrombosis of other cerebral artery
I63.40	Cerebral infarction due to embolism of unspecified cerebral artery
I63.411	Cerebral infarction due to embolism of right middle cerebral artery
I63.412	Cerebral infarction due to embolism of left middle cerebral artery
I63.413	Cerebral infarction due to embolism of bilateral middle cerebral arteries
I63.419	Cerebral infarction due to embolism of unspecified middle cerebral artery
I63.421	Cerebral infarction due to embolism of right anterior cerebral artery
I63.422	Cerebral infarction due to embolism of left anterior cerebral artery
I63.423	Cerebral infarction due to embolism of bilateral anterior cerebral arteries
I63.429	Cerebral infarction due to embolism of unspecified anterior cerebral artery
I63.431	Cerebral infarction due to embolism of right posterior cerebral artery
I63.432	Cerebral infarction due to embolism of left posterior cerebral artery
I63.433	Cerebral infarction due to embolism of bilateral posterior cerebral arteries
I63.439	Cerebral infarction due to embolism of unspecified posterior cerebral artery
I63.441	Cerebral infarction due to embolism of right cerebellar artery
I63.442	Cerebral infarction due to embolism of left cerebellar artery
I63.443	Cerebral infarction due to embolism of bilateral cerebellar arteries
I63.449	Cerebral infarction due to embolism of unspecified cerebellar artery
I63.49	Cerebral infarction due to embolism of other cerebral artery

Important Safety Information (cont'd)

The once-monthly (Q4W) 300mg dosing regimen had a higher rate of local injection site reactions as compared to PRALUENT 75mg Q2W or placebo (16.6%, 9.6%, and 7.9%, respectively). The discontinuation rate due to injection site reactions was 0.7% in the 300 mg Q4W arm and 0% in the other 2 arms.

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information.

Praluent[®]
(alirocumab) Injection 75mg/mL
150mg/mL

I63: Cerebral infarction (cont'd)

I63.50	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebral artery
I63.511	Cerebral infarction due to unspecified occlusion or stenosis of right middle cerebral artery
I63.512	Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral artery
I63.513	Cerebral infarction due to unspecified occlusion or stenosis of bilateral middle cerebral arteries
I63.519	Cerebral infarction due to unspecified occlusion or stenosis of unspecified middle cerebral artery
I63.52	Cerebral infarction due to unspecified occlusion or stenosis of anterior cerebral artery
I63.521	Cerebral infarction due to unspecified occlusion or stenosis of right anterior cerebral artery
I63.522	Cerebral infarction due to unspecified occlusion or stenosis of left anterior cerebral artery
I63.523	Cerebral infarction due to unspecified occlusion or stenosis of bilateral anterior cerebral arteries
I63.529	Cerebral infarction due to unspecified occlusion or stenosis of unspecified anterior cerebral artery
I63.53	Cerebral infarction due to unspecified occlusion or stenosis of posterior cerebral artery
I63.531	Cerebral infarction due to unspecified occlusion or stenosis of right posterior cerebral artery
I63.532	Cerebral infarction due to unspecified occlusion or stenosis of left posterior cerebral artery
I63.533	Cerebral infarction due to unspecified occlusion or stenosis of bilateral posterior cerebral arteries
I63.539	Cerebral infarction due to unspecified occlusion or stenosis of unspecified posterior cerebral artery
I63.54	Cerebral infarction due to unspecified occlusion or stenosis of cerebellar artery
I63.541	Cerebral infarction due to unspecified occlusion or stenosis of right cerebellar artery
I63.542	Cerebral infarction due to unspecified occlusion or stenosis of left cerebellar artery
I63.543	Cerebral infarction due to unspecified occlusion or stenosis of bilateral cerebellar arteries
I63.549	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebellar artery
I63.59	Cerebral infarction due to unspecified occlusion or stenosis of other cerebral artery
I63.6	Cerebral infarction due to cerebral venous thrombosis, nonpyogenic
I63.8	Other cerebral infarction
I63.9	Cerebral infarction, unspecified

I65: Occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction

I65.0	Occlusion and stenosis of vertebral artery
I65.01	Occlusion and stenosis of right vertebral artery
I65.02	Occlusion and stenosis of left vertebral artery
I65.03	Occlusion and stenosis of bilateral vertebral arteries
I65.09	Occlusion and stenosis of unspecified vertebral artery
I65.1	Occlusion and stenosis of basilar artery
I65.2	Occlusion and stenosis of carotid artery
I65.21	Occlusion and stenosis of right carotid artery
I65.22	Occlusion and stenosis of left carotid artery
I65.23	Occlusion and stenosis of bilateral carotid arteries
I65.29	Occlusion and stenosis of unspecified carotid artery
I65.8	Occlusion and stenosis of other precerebral arteries
I65.9	Occlusion and stenosis of unspecified precerebral artery

Important Safety Information (cont'd)

In a cardiovascular outcomes trial, local injection site reactions were reported in 3.8% of patients treated with PRALUENT versus 2.1% patients treated with placebo, and led to permanent discontinuation in 0.3% of patients versus <0.1% of patients, respectively.

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information.

Praluent[®]
(alirocumab) Injection 75mg/mL
150mg/mL

I66: Occlusion and stenosis of cerebral arteries, not resulting in cerebral infarction

I66.0	Occlusion and stenosis of middle cerebral artery
I66.01	Occlusion and stenosis of right middle cerebral artery
I66.02	Occlusion and stenosis of left middle cerebral artery
I66.03	Occlusion and stenosis of bilateral middle cerebral arteries
I66.09	Occlusion and stenosis of unspecified middle cerebral artery
I66.1	Occlusion and stenosis of anterior cerebral artery
I66.11	Occlusion and stenosis of right anterior cerebral artery
I66.12	Occlusion and stenosis of left anterior cerebral artery
I66.13	Occlusion and stenosis of bilateral anterior cerebral arteries
I66.19	Occlusion and stenosis of unspecified anterior cerebral artery
I66.2	Occlusion and stenosis of posterior cerebral artery
I66.21	Occlusion and stenosis of right posterior cerebral artery
I66.22	Occlusion and stenosis of left posterior cerebral artery
I66.23	Occlusion and stenosis of bilateral posterior cerebral arteries
I66.29	Occlusion and stenosis of unspecified posterior cerebral artery
I66.3	Occlusion and stenosis of cerebellar arteries
I66.8	Occlusion and stenosis of other cerebral arteries
I66.9	Occlusion and stenosis of unspecified cerebral artery

I67: Other cerebrovascular diseases

I67.2	Cerebral atherosclerosis
I67.81	Acute cerebrovascular insufficiency
I67.82	Cerebral ischemia

Important Safety Information (cont'd)

In the primary hyperlipidemia trials, liver-related disorders (primarily related to abnormalities in liver enzymes) were reported in 2.5% of patients treated with PRALUENT and 1.8% of patients treated with placebo, leading to treatment discontinuation in 0.4% and 0.2% of patients, respectively. Increases in serum transaminases to greater than 3 times the upper limit of normal occurred in 1.7% of patients treated with PRALUENT and 1.4% of patients treated with placebo.

In the primary hyperlipidemia trials, the most common adverse reactions leading to treatment discontinuation in patients treated with PRALUENT were allergic reactions (0.6% versus 0.2% for PRALUENT and placebo, respectively) and elevated liver enzymes (0.3% versus <0.1%).

PRALUENT is a human monoclonal antibody. As with all therapeutic proteins, there is a potential for immunogenicity with PRALUENT.

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information.

Praluent[®]
(alirocumab) Injection 75mg/mL
150mg/mL

Diseases of arteries, arterioles, and capillaries

I70: Atherosclerosis

I70.0	Atherosclerosis of aorta
I70.1	Atherosclerosis of renal artery
I70.2	Atherosclerosis of native arteries of the extremities
I70.20	Unspecified atherosclerosis of native arteries of extremities
I70.201	Unspecified atherosclerosis of native arteries of extremities, right leg
I70.202	Unspecified atherosclerosis of native arteries of extremities, left leg
I70.203	Unspecified atherosclerosis of native arteries of extremities, bilateral legs
I70.208	Unspecified atherosclerosis of native arteries of extremities, other extremity
I70.209	Unspecified atherosclerosis of native arteries of extremities, unspecified extremity
I70.21	Atherosclerosis of native arteries of extremities with intermittent claudication
I70.211	Atherosclerosis of native arteries of extremities with intermittent claudication, right leg
I70.212	Atherosclerosis of native arteries of extremities with intermittent claudication, left leg
I70.213	Atherosclerosis of native arteries of extremities with intermittent claudication, bilateral legs
I70.218	Atherosclerosis of native arteries of extremities with intermittent claudication, other extremity
I70.219	Atherosclerosis of native arteries of extremities with intermittent claudication, unspecified extremity
I70.22	Atherosclerosis of native arteries of extremities with rest pain
I70.221	Atherosclerosis of native arteries of extremities with rest pain, right leg
I70.222	Atherosclerosis of native arteries of extremities with rest pain, left leg
I70.223	Atherosclerosis of native arteries of extremities with rest pain, bilateral legs
I70.228	Atherosclerosis of native arteries of extremities with rest pain, other extremity
I70.229	Atherosclerosis of native arteries of extremities with rest pain, unspecified extremity
I70.23	Atherosclerosis of native arteries of right leg with ulceration
I70.231	Atherosclerosis of native arteries of right leg with ulceration of thigh
I70.232	Atherosclerosis of native arteries of right leg with ulceration of calf
I70.233	Atherosclerosis of native arteries of right leg with ulceration of ankle
I70.234	Atherosclerosis of native arteries of right leg with ulceration of heel and midfoot
I70.235	Atherosclerosis of native arteries of right leg with ulceration of other part of foot
I70.238	Atherosclerosis of native arteries of right leg with ulceration of other part of lower right leg
I70.239	Atherosclerosis of native arteries of right leg with ulceration of unspecified site
I70.24	Atherosclerosis of native arteries of left leg with ulceration
I70.241	Atherosclerosis of native arteries of left leg with ulceration of thigh
I70.242	Atherosclerosis of native arteries of left leg with ulceration of calf
I70.243	Atherosclerosis of native arteries of left leg with ulceration of ankle
I70.244	Atherosclerosis of native arteries of left leg with ulceration of heel and midfoot
I70.245	Atherosclerosis of native arteries of left leg with ulceration of other part of foot
I70.248	Atherosclerosis of native arteries of left leg with ulceration of other part of lower left leg
I70.249	Atherosclerosis of native arteries of left leg with ulceration of unspecified site
I70.25	Atherosclerosis of native arteries of other extremities with ulceration

Important Safety Information

PRALUENT is contraindicated in patients with a history of a serious hypersensitivity reaction to alirocumab or any of the excipients in PRALUENT. Hypersensitivity reactions, including hypersensitivity vasculitis, angioedema, and other hypersensitivity reactions requiring hospitalization, have been reported with PRALUENT treatment. If signs or symptoms of serious allergic reactions occur, discontinue treatment with PRALUENT, treat according to the standard of care, and monitor until signs and symptoms resolve.

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information.

Praluent[®]
(alirocumab) Injection 75mg/mL
150mg/mL

I70: Atherosclerosis (cont'd)

I70.26	Atherosclerosis of native arteries of extremities with gangrene
I70.261	Atherosclerosis of native arteries of extremities with gangrene, right leg
I70.262	Atherosclerosis of native arteries of extremities with gangrene, left leg
I70.263	Atherosclerosis of native arteries of extremities with gangrene, bilateral legs
I70.268	Atherosclerosis of native arteries of extremities with gangrene, other extremity
I70.269	Atherosclerosis of native arteries of extremities with gangrene, unspecified extremity
I70.29	Other atherosclerosis of native arteries of extremities
I70.291	Other atherosclerosis of native arteries of extremities, right leg
I70.292	Other atherosclerosis of native arteries of extremities, left leg
I70.293	Other atherosclerosis of native arteries of extremities, bilateral legs
I70.298	Other atherosclerosis of native arteries of extremities, other extremity
I70.299	Other atherosclerosis of native arteries of extremities, unspecified extremity
I70.3	Atherosclerosis of unspecified type of bypass graft(s) of the extremities
I70.30	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities
I70.301	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, right leg
I70.302	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, left leg
I70.303	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, bilateral legs
I70.308	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, other extremity
I70.309	Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, unspecified extremity
I70.31	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication
I70.311	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, right leg
I70.312	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, left leg
I70.313	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, bilateral legs
I70.318	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, other extremity
I70.319	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, unspecified extremity
I70.32	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain
I70.321	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, right leg
I70.322	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, left leg
I70.323	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, bilateral legs
I70.328	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, other extremity
I70.329	Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, unspecified extremity
I70.331	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of thigh
I70.332	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of calf
I70.333	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of ankle
I70.334	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of heel and midfoot
I70.335	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of other part of foot
I70.338	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of other part of lower leg
I70.339	Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of unspecified site
I70.34	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration
I70.341	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of thigh
I70.342	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of calf
I70.343	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of ankle
I70.344	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of heel and midfoot
I70.345	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of other part of foot
I70.348	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of other part of lower leg
I70.349	Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of unspecified site

Important Safety Information (cont'd)

The most commonly occurring adverse reactions in clinical trials in primary hyperlipidemia (including heterozygous familial hypercholesterolemia (HeFH)) ($\geq 5\%$ of patients treated with PRALUENT and occurring more frequently than with placebo) are nasopharyngitis, injection site reactions, and influenza.

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information.

Praluent[®]
(alirocumab) Injection 75mg/mL
150mg/mL

I70: Atherosclerosis (cont'd)

- I70.35** Atherosclerosis, unspecified type of bypass graft(s) of other extremity with ulceration
- I70.36** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene
- I70.361** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, right leg
- I70.362** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, left leg
- I70.363** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, bilateral legs
- I70.368** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, other extremity
- I70.369** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, unspecified extremity
- I70.39** Other atherosclerosis of unspecified type of bypass graft(s) of the extremities
- I70.391** Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, right leg
- I70.392** Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, left leg
- I70.393** Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, bilateral legs
- I70.398** Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, other extremity
- I70.399** Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, unspecified extremity
- I70.4** Atherosclerosis of autologous vein bypass graft(s) of the extremities
- I70.40** Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities
- I70.401** Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities, right leg
- I70.402** Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities, left leg
- I70.403** Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities, bilateral legs
- I70.408** Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities, other extremity
- I70.409** Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities, unspecified extremity
- I70.41** Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication
- I70.411** Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication, right leg
- I70.412** Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication, left leg
- I70.413** Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication, bilateral legs
- I70.418** Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication, other extremity
- I70.419** Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication, unspecified extremity
- I70.42** Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain
- I70.421** Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, right leg
- I70.422** Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, left leg
- I70.423** Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, bilateral legs
- I70.428** Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, other extremity
- I70.429** Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, unspecified extremity
- I70.43** Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration
- I70.431** Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of thigh
- I70.432** Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of calf
- I70.433** Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of ankle
- I70.434** Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of heel and midfoot
- I70.435** Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of other part of foot
- I70.438** Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of other part of lower leg
- I70.439** Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of unspecified site
- I70.44** Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration
- I70.441** Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of thigh
- I70.442** Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of calf
- I70.443** Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of ankle
- I70.444** Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of heel and midfoot
- I70.445** Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of other part of foot

Important Safety Information (cont'd)

The most commonly occurring adverse reactions in the cardiovascular outcomes trial (>5% of patients treated with PRALUENT and occurring more frequently than placebo) were non-cardiac chest pain, nasopharyngitis, and myalgia.

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information.

Praluent[®]
(alirocumab) Injection 75mg/mL
150mg/mL

I70: Atherosclerosis (cont'd)

- I70.448** Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of other part of lower leg
- I70.449** Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of unspecified site
- I70.45** Atherosclerosis of autologous vein bypass graft(s) of other extremity with ulceration
- I70.46** Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene
- I70.461** Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, right leg
- I70.462** Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, left leg
- I70.463** Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, bilateral legs
- I70.468** Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, other extremity
- I70.469** Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, unspecified extremity
- I70.491** Other atherosclerosis of autologous vein bypass graft(s) of the extremities, right leg
- I70.492** Other atherosclerosis of autologous vein bypass graft(s) of the extremities, left leg
- I70.493** Other atherosclerosis of autologous vein bypass graft(s) of the extremities, bilateral legs
- I70.498** Other atherosclerosis of autologous vein bypass graft(s) of the extremities, other extremity
- I70.499** Other atherosclerosis of autologous vein bypass graft(s) of the extremities, unspecified extremity
- I70.5** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities
- I70.50** Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities
- I70.501** Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, right leg
- I70.502** Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, left leg
- I70.503** Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, bilateral legs
- I70.508** Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, other extremity
- I70.509** Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, unspecified extremity
- I70.51** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities intermittent claudication
- I70.511** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, right leg
- I70.512** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, left leg
- I70.513** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, bilateral legs
- I70.518** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, other extremity
- I70.519** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, unspecified extremity
- I70.52** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain
- I70.521** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, right leg
- I70.522** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, left leg
- I70.523** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, bilateral legs
- I70.528** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, other extremity
- I70.529** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, unspecified extremity
- I70.53** Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration
- I70.531** Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of thigh
- I70.532** Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of calf
- I70.533** Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of ankle
- I70.534** Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of heel and midfoot
- I70.535** Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of other part of foot
- I70.538** Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of other part of lower leg
- I70.539** Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of unspecified site
- I70.54** Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration

Important Safety Information (cont'd)

In the primary hyperlipidemia (including HeFH) clinical trials, local injection site reactions including erythema/redness, itching, swelling, and pain/tenderness were reported more frequently in patients treated with PRALUENT 75 mg and/or 150 mg every 2 weeks (7.2% versus 5.1% for PRALUENT and placebo, respectively).

Few patients discontinued treatment because of these reactions (0.2% versus 0.4% for PRALUENT and placebo, respectively), but patients receiving PRALUENT had a greater number of injection site reactions, had more reports of associated symptoms, and had reactions of longer average duration than patients receiving placebo.

Please see additional Important Safety Information throughout and [click here for full Prescribing Information](#).

Praluent[®]
(alirocumab) Injection 75mg/mL
150mg/mL

I70: Atherosclerosis (cont'd)

- I70.541 Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of thigh
- I70.542 Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of calf
- I70.543 Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of ankle
- I70.544 Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of heel and midfoot
- I70.545 Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of other part of foot
- I70.548 Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of other part of lower leg
- I70.549 Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of unspecified site
- I70.55 Atherosclerosis of nonautologous biological bypass graft(s) of other extremity with ulceration
- I70.56 Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene
- I70.561 Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, right leg
- I70.562 Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, left leg
- I70.563 Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, bilateral legs
- I70.568 Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, other extremity
- I70.569 Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, unspecified extremity
- I70.59 Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities
- I70.591 Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, right leg
- I70.592 Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, left leg
- I70.593 Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, bilateral legs
- I70.598 Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, other extremity
- I70.599 Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, unspecified extremity
- I70.6 Atherosclerosis of nonbiological bypass graft(s) of the extremities
- I70.60 Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities
- I70.601 Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, right leg
- I70.602 Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, left leg
- I70.603 Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, bilateral legs
- I70.608 Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, other extremity
- I70.609 Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, unspecified extremity
- I70.61 Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication
- I70.611 Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, right leg
- I70.612 Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, left leg
- I70.613 Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, bilateral legs
- I70.618 Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, other extremity
- I70.619 Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, unspecified extremity
- I70.62 Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain
- I70.621 Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, right leg
- I70.622 Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, left leg
- I70.623 Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, bilateral legs
- I70.628 Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, other extremity
- I70.629 Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, unspecified extremity
- I70.63 Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration
- I70.631 Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of thigh
- I70.632 Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of calf
- I70.633 Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of ankle

Important Safety Information (cont'd)

The once-monthly (Q4W) 300mg dosing regimen had a higher rate of local injection site reactions as compared to PRALUENT 75mg Q2W or placebo (16.6%, 9.6%, and 7.9%, respectively). The discontinuation rate due to injection site reactions was 0.7% in the 300 mg Q4W arm and 0% in the other 2 arms.

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information.



Praluent[®]
(alirocumab) Injection 75mg/mL
150mg/mL

I70: Atherosclerosis (cont'd)

- I70.634 Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of heel and midfoot
- I70.635 Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of other part of foot
- I70.638 Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of other part of lower leg
- I70.639 Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of unspecified site
- I70.64 Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration
- I70.641 Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of thigh
- I70.642 Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of calf
- I70.643 Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of ankle
- I70.644 Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of heel and midfoot
- I70.645 Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of other part of foot
- I70.648 Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of other part of lower leg
- I70.649 Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of unspecified site
- I70.65 Atherosclerosis of nonbiological bypass graft(s) of other extremity with ulceration
- I70.66 Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene
- I70.661 Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, right leg
- I70.662 Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, left leg
- I70.663 Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, bilateral legs
- I70.668 Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, other extremity
- I70.669 Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, unspecified extremity
- I70.69 Other atherosclerosis of nonbiological bypass graft(s) of the extremities
- I70.691 Other atherosclerosis of nonbiological bypass graft(s) of the extremities, right leg
- I70.692 Other atherosclerosis of nonbiological bypass graft(s) of the extremities, left leg
- I70.693 Other atherosclerosis of nonbiological bypass graft(s) of the extremities, bilateral legs
- I70.698 Other atherosclerosis of nonbiological bypass graft(s) of the extremities, other extremity
- I70.699 Other atherosclerosis of nonbiological bypass graft(s) of the extremities, unspecified extremity
- I70.7 Atherosclerosis of other type of bypass graft(s) of the extremities
- I70.70 Unspecified atherosclerosis of other type of bypass graft(s) of the extremities
- I70.701 Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, right leg
- I70.702 Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, left leg
- I70.703 Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, bilateral legs
- I70.708 Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, other extremity
- I70.709 Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, unspecified extremity
- I70.71 Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication
- I70.711 Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, right leg
- I70.712 Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, left leg
- I70.713 Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, bilateral legs
- I70.718 Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, other extremity
- I70.719 Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, unspecified extremity
- I70.72 Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain
- I70.721 Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, right leg
- I70.722 Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, left leg
- I70.723 Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, bilateral legs

Important Safety Information (cont'd)

In a cardiovascular outcomes trial, local injection site reactions were reported in 3.8% of patients treated with PRALUENT versus 2.1% patients treated with placebo, and led to permanent discontinuation in 0.3% of patients versus <0.1% of patients, respectively.

Please see additional Important Safety Information throughout and [click here](#) for full Prescribing Information.

Praluent[®]
(alirocumab) Injection 75mg/mL
150mg/mL

I70: Atherosclerosis (cont'd)

I70.728	Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, other extremity
I70.729	Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, unspecified extremity
I70.73	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration
I70.731	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of thigh
I70.732	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of calf
I70.733	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of ankle
I70.734	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of heel and midfoot
I70.735	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of other part of foot
I70.738	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of other part of lower leg
I70.739	Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of unspecified site
I70.74	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration
I70.741	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of thigh
I70.742	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of calf
I70.743	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of ankle
I70.744	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of heel and midfoot
I70.745	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of other part of foot
I70.748	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of other part of lower leg
I70.749	Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of unspecified site
I70.75	Atherosclerosis of other type of bypass graft(s) of other extremity with ulceration
I70.76	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene
I70.761	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, right leg
I70.762	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, left leg
I70.763	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, bilateral legs
I70.768	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, other extremity
I70.769	Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, unspecified extremity
I70.79	Other atherosclerosis of other type of bypass graft(s) of the extremities
I70.791	Other atherosclerosis of other type of bypass graft(s) of the extremities, right leg
I70.792	Other atherosclerosis of other type of bypass graft(s) of the extremities, left leg
I70.793	Other atherosclerosis of other type of bypass graft(s) of the extremities, bilateral legs
I70.798	Other atherosclerosis of other type of bypass graft(s) of the extremities, other extremity
I70.799	Other atherosclerosis of other type of bypass graft(s) of the extremities, unspecified extremity
I70.8	Atherosclerosis of other arteries
I70.9	Other and unspecified atherosclerosis
I70.91	Generalized atherosclerosis
I70.92	Chronic total occlusion of artery of extremities

I73: Other peripheral vascular diseases

I73.8	Other specified peripheral vascular diseases
I73.9	Peripheral vascular disease, unspecified

Important Safety Information (cont'd)

In the primary hyperlipidemia trials, liver-related disorders (primarily related to abnormalities in liver enzymes) were reported in 2.5% of patients treated with PRALUENT and 1.8% of patients treated with placebo, leading to treatment discontinuation in 0.4% and 0.2% of patients, respectively. Increases in serum transaminases to greater than 3 times the upper limit of normal occurred in 1.7% of patients treated with PRALUENT and 1.4% of patients treated with placebo.

In the primary hyperlipidemia trials, the most common adverse reactions leading to treatment discontinuation in patients treated with PRALUENT were allergic reactions (0.6% versus 0.2% for PRALUENT and placebo, respectively) and elevated liver enzymes (0.3% versus <0.1%).

Please see additional Important Safety Information throughout and [click here for full Prescribing Information](#).

Praluent[®]
(alirocumab) Injection 75mg/mL
150mg/mL

Z83: Family history of other specific disorders

Z83.42 Family history of familial hypercholesterolemia

Z95: Presence of cardiac and vascular implants and grafts

Z95.1 Presence of aortocoronary bypass graft

Z95.5 Presence of coronary angioplasty implant and graft

Z95.820 Peripheral vascular angioplasty status with implants and grafts

Z98: Other postprocedural states

Z98.6 Angioplasty status

Z98.61 Coronary angioplasty status

Z98.62 Peripheral vascular angioplasty status

Need additional support?Call **1-844-PRALUENT** (1-844-772-5836), Monday–Friday, 8 AM–8 PM Eastern time or visit **PRALUENThcp.com****Frequently used codes for my office***Use this section to keep track of the ICD-10-CM diagnosis codes that your office uses when prescribing PRALUENT or enrolling patients in MyPRALUENT®.*

ICD-10-CM diagnosis code	Code description

Important Safety Information (cont'd)

PRALUENT is a human monoclonal antibody. As with all therapeutic proteins, there is a potential for immunogenicity with PRALUENT.

Reference: 1. 2021 ICD-10-CM. Centers for Medicare & Medicaid Services website. <https://www.cms.gov/medicare/icd-10/2021-icd-10-cm>. Updated December 16, 2020. Accessed February 17, 2021.Please [click here](#) for full Prescribing Information.**REGENERON**©2021 Regeneron Pharmaceuticals, Inc. All rights reserved.
04/2021 PRA.21.02.0054


Praluent[®]
(alirocumab) Injection 75mg/mL
150mg/mL